Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection

Table 1 The demographic and laboratory data of all patients (mean ± SD)

Item	Non-cirrhotic group (F0, F1, F2 and F3)	Cirrhotic group (F4)	P value
	n (124)	n (30)
Age, yr	37.19 ± 9.58	47.87 ± 7.76	0.0002
Gender, n (%)
Male	86 (69.35)	18 (60)
Female	38 (30.65)	12 (40)
AST (IU/mL)	48.84 ± 42.7	61 ± 20.4	0.01
ALT (IU/mL)	60.235 ± 42.3	57.7 ± 24.69	0.68
Alkaline phosphatase (U/L)	81.654 ± 38.4	111 ± 42.5	0.004
Total bilirubin (mg/dL)	0.787 ± 0.30	1.003 ± 0.38	0.07
Albumin (g/dL)	5.803 ± 0.789	4.1 ± 0.42	0.004
INR	1.127 ± 0.092	1.254 ± 0.12	0.0001
Platelet count (/mm3)	213.75 ± 66.1	151.87 ± 73.79	0.001
HCV viraemia, IU/mL	893 015.72 ± 1 571 254.86	347 974.86 ± 536 542.77	0.23

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; INR: International normalized ratio; HCV: Hepatitis C virus.